Can I Take Omega-3 (EPA/DHA) with Provigil (Modafinil)?

Modafinil (brand name Provigil) is a wakefulness-promoting agent, chemically distinct from amphetamine-type stimulants, FDA-approved for excessive daytime sleepiness associated with narcolepsy, obstructive sleep apnea (used alongside the primary OSA treatment, not as a replacement for it), and shift-work sleep disorder. Omega-3 fatty acids, specifically EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), are essential fatty acids available as over-the-counter fish oil or algae-oil supplements, and as prescription products (icosapentaenoic acid, brand Vascepa; omega-3-acid ethyl esters, brand Lovaza) used for triglyceride reduction.

No controlled trial has tested omega-3 fatty acids combined with modafinil, and no pharmacokinetic drug-supplement interaction between them has been reported in the literature reviewed for this page. Modafinil is metabolized mainly through CYP3A4/3A5, and standard omega-3 doses do not meaningfully inhibit or induce that pathway [1][2]. The one pharmacodynamic signal worth tracking is platelet function: omega-3 has antiplatelet activity that becomes more clinically relevant at intakes above roughly 3 g EPA+DHA per day, particularly in someone already taking an anticoagulant or antiplatelet drug. That risk comes from the omega-3 dose and the rest of the regimen, not from modafinil itself.

What is established, what is plausible, and what is not established

Established: Omega-3 fatty acids do not meaningfully affect the CYP3A4/CYP2C19 enzymes that clear modafinil, based on in-vitro enzyme kinetics data [2]. Modafinil has no documented antiplatelet or lipid-lowering activity of its own, based on its original narcolepsy trial data [1].

Plausible but unproven: That combining a stimulant-class wakefulness agent with high-dose omega-3 in a patient with cardiovascular risk factors warrants closer blood pressure and heart rate monitoring. This is a reasonable extrapolation from each agent's individual cardiovascular profile, not a finding from a study that tested the combination.

Not established: That omega-3 supplementation enhances, blunts, or otherwise changes modafinil's wakefulness or cognitive effects. No published trial has co-administered the two agents to measure this. Any claim of a combined cognitive benefit is mechanistic reasoning, not clinical evidence.

Is this an off-label question?

Taking a dietary supplement alongside an FDA-approved medication is not itself an off-label use, but the reason someone is taking modafinil affects how cautiously the combination should be approached. Modafinil is FDA-approved only for the three indications above [1]. Use for general cognitive enhancement in people without one of those diagnoses is off-label, and the evidence base for that use is thinner than for the approved indications.

Modafinil has also been studied as an off-label augmentation option when antidepressant treatment for major depressive disorder produces only a partial response. A 2009 review of switching and augmentation strategies for MDD lists modafinil among the adjunctive options clinicians have considered in that context [10]. That paper discusses treatment strategy in depression generally; it does not evaluate modafinil's pharmacology in detail and says nothing about omega-3 co-administration, so it should not be read as evidence about this specific interaction, only as context for why modafinil sometimes appears in psychiatric regimens where omega-3 supplementation is also common.

How modafinil is metabolized, and why that matters for a supplement

Modafinil reaches peak plasma concentration around 2 to 4 hours after an oral dose and has a half-life of roughly 12 to 15 hours [1]. It is cleared mainly through hepatic CYP3A4/3A5, with a smaller role for CYP2C19. At steady state it also weakly induces CYP3A4 and inhibits CYP2C19, which matters for drugs that depend heavily on those enzymes for clearance, such as certain hormonal contraceptives, diazepam, or omeprazole.

An in-vitro study of polyunsaturated fatty acids and human CYP enzymes found no significant inhibition of the CYP pathways examined at physiologically relevant concentrations [2]. That is the closest available evidence to a direct pharmacokinetic answer, and it points toward no meaningful interaction, though it is bench data rather than a human pharmacokinetic trial in people taking modafinil.

Modafinil is roughly 60% protein-bound, mainly to albumin, as are EPA and DHA during transport. Protein-displacement interactions are rarely clinically significant unless both agents are highly protein-bound with a narrow therapeutic window; neither modafinil nor omega-3 supplements fit that profile. Modafinil absorption is not meaningfully food-dependent, so there is no established need to separate fish-oil capsules from a modafinil dose by time of day.

The antiplatelet question: when does dose matter?

EPA and DHA inhibit platelet aggregation partly by competing with arachidonic acid for cyclooxygenase and reducing thromboxane A2 production, alongside anti-inflammatory effects mediated by resolvins and protectins [3]. A typical over-the-counter fish-oil capsule provides roughly 300 to 600 mg combined EPA+DHA, and a common supplemental dose of 1 to 2 g/day produces an antiplatelet effect that is generally regarded as mild.

A study of omega-3 ethyl esters combined with aspirin in healthy volunteers examined platelet function at doses in the range used by prescription omega-3 products and found measurable additive antiplatelet activity when combined with aspirin [6]. That study does not establish one universal dose cutoff below which no effect exists; it supports the more general and more defensible statement that antiplatelet activity is more consistently seen at the 3 to 4 g/day doses used in prescription omega-3 products than at typical over-the-counter supplement doses. The REDUCE-IT trial, which tested icosapentaenoic acid at 4 g/day in over 8,000 patients, did not find a significant excess of bleeding events versus placebo, though it did find more atrial fibrillation and peripheral edema in the treatment group [4]. That is reassuring for high-dose EPA monotherapy but does not directly address a modafinil combination, since REDUCE-IT was not designed to test that.

Modafinil itself has no documented antiplatelet activity. No case reports of clinically significant bleeding attributed specifically to a modafinil-plus-omega-3 combination were identified in the sources reviewed for this article; that absence reflects a lack of published reports rather than a systematic safety study of the combination.

Evidence-status interaction assessment

Cognitive effects: complementary pathways, but no combined trial

Modafinil promotes wakefulness primarily by blocking dopamine reuptake and by activating orexin/hypocretin signaling [1]. EPA and DHA support neuronal membrane composition, have anti-inflammatory effects through resolvin and protectin pathways, and have been studied for effects on attention and processing speed independent of modafinil [3][8]. A randomized trial in healthy adults found that 1.25 g/day of EPA+DHA over 26 weeks improved attention and processing speed scores compared with placebo [8]. That effect, where it exists, is smaller and slower to develop than modafinil's acute wakefulness effect, and the two mechanisms do not appear to conflict.

No published trial has combined the two agents to measure a joint cognitive outcome. Reasoning that omega-3's anti-inflammatory effect might help maintain modafinil's effectiveness over time is mechanistically plausible but unproven, and should not be presented to a patient as an established benefit.

Triglycerides and cardiovascular risk

Prescription-strength omega-3 products can produce substantial reductions in fasting triglycerides; FDA labeling for icosapentaenoic acid describes meaningful reductions depending on baseline triglyceride level [7]. Modafinil's original narcolepsy trials did not find significant changes in total cholesterol, LDL, HDL, or triglycerides at doses of 200 to 400 mg/day [1], so starting omega-3 therapy for lipid management does not require a modafinil dose change on that basis.

Modafinil's prescribing information notes that it has not been evaluated to any appreciable extent in patients with a recent history of myocardial infarction or unstable angina, and that such patients should be treated with caution [1]. That caution is independent of omega-3 use, but it becomes more relevant if a patient with existing cardiac risk factors is also starting a high-dose omega-3 product, since the reasons for extra monitoring (cardiac history) are the same in both cases.

Practical guidance by patient profile

Healthy adults without anticoagulant therapy. Standard omega-3 supplementation (roughly 1 to 2 g EPA+DHA/day) alongside modafinil requires no special timing adjustment. Mention the supplement at routine medication reviews.

Adults on warfarin or a direct oral anticoagulant. Confirm with your prescriber before adding omega-3 above roughly 1 g/day. More frequent INR monitoring is often reasonable for several weeks after starting or changing an omega-3 dose. This precaution is about the anticoagulant and the omega-3, not about modafinil.

Adults on aspirin or regular NSAIDs. At omega-3 doses below the 3 to 4 g/day range used in prescription products, the added antiplatelet effect is generally considered modest. Above that range, discuss it with your prescriber and watch for unusual bruising, bleeding that takes longer than usual to stop, or blood in stool or urine.

Anyone considering surgery. Standard pre-surgical guidance often calls for stopping omega-3 supplements at doses above roughly 1 to 2 g/day about a week to ten days before an elective procedure because of antiplatelet activity; confirm the exact timing with the surgical team. Modafinil's relevant surgical consideration is a separate one, related to interaction with anesthesia and CNS stimulant effects, and should be discussed with the anesthesiologist independently.

People taking modafinil off-label, including for depression augmentation. The interaction assessment above does not change based on why modafinil is being used. What changes is that off-label use generally means less direct trial evidence overall, so any new symptom after adding a supplement deserves a lower threshold for checking in with the prescriber.

What to tell your prescriber or pharmacist

• The specific omega-3 product and daily dose in milligrams of EPA and DHA combined (a concentrated prescription product like Vascepa is not the same as a standard fish-oil capsule)
• Any other supplement with antiplatelet properties, such as vitamin E above 400 IU, garlic extract, ginkgo biloba, or nattokinase
• Any anticoagulant or antiplatelet medication, including low-dose aspirin
• Any new bruising, bleeding, chest pain, irregular heartbeat, or skin changes since starting either agent

The American Heart Association's 2017 science advisory notes roughly 1 g/day of EPA+DHA for people with documented coronary heart disease, and higher doses of 2 to 4 g/day under physician supervision for people with elevated triglycerides [9]. Those recommendations are not modafinil-specific, but they set the dose context in which the antiplatelet question above becomes relevant.

Bottom line

For most adults taking modafinil for an FDA-approved indication and a standard over-the-counter fish-oil supplement, current evidence does not point to a meaningful pharmacokinetic or pharmacodynamic problem. The situation that deserves a specific conversation with a prescriber is a high-dose omega-3 product (in the 3 to 4 g/day range) combined with an anticoagulant or antiplatelet medication, independent of the modafinil. This page does not address individual dosing decisions; a prescriber or pharmacist who knows the full medication list should make that call.